Commentary by Christian Brunnstrom, research analyst, ESG & impact investing
Titan Medical's corporate governance and leadership is in the spotlight after the Canadian medical-device company said that it no longer complied with the Nasdaq listing qualifications that require a majority of a company's board members and audit committee members to be independent. Following the recent resignation of Heather Knight, one of its independent directors, only two of the company's four board members are independent. Titan Medical's board is unusually small, as the average S&P 500 board has 11 directors and more than 80% independent directors, according to FactSet data. Ms. Knight's resignation also meant a drop in gender equity on Titan Medical's board from 40% to 25%, lower than the 30% average female representation on the S&P 500, the data shows. Titan Medical has been given up to February 2024, or before the first week of August this year if the company holds its next annual shareholder meeting before then, to comply with the Nasdaq rules for independent board and audit committee members. In addition, Titan Medical announced several senior leadership changes on Tuesday, laying off four vice presidents. The company's governance and leadership is likely to stay on investors' radar for the time being.
Write to Christian Brunnstrom at christian.brunnstrom@wsj.com
ESG Insights are written by WSJ Pro Research analysts, whose commentary is independent of the news coverage by reporters at the Journal.
(END) Dow Jones Newswires
February 15, 2023 05:20 ET (10:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。